Drug delivery to peroxisomes: Employing unique trafficking mechanisms to target protein therapeutics

Advanced Drug Delivery Reviews

Volumn 59, Issue 8, 2007, Pages 739-747

  Terlecky, Stanley R ^a   Koepke, Jay I ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EXT Life Sciences Inc   (United States)

Author keywords

Aging; Biogenesis; Human peroxisomal disorders; Protein transduction; Reactive oxygen species; Targeting signals

Indexed keywords

BIOCHEMISTRY; BIOSYNTHESIS; CELLS; DETOXIFICATION; DRUG DELIVERY; METABOLISM;

HUMAN PEROXISOMAL DISORDERS; PROTEIN TRANSDUCTION; REACTIVE OXYGEN SPECIES; TARGETING SIGNALS;

PROTEINS;

2 METHYLACYL COENZYME A RACEMASE; ACYL COENZYME A OXIDASE; ANTIOXIDANT; CATALASE; CELL PENETRATING PEPTIDE; FATTY ACID; GLYOXYLIC ACID; HEPARIN; HYDROGEN PEROXIDE; IMMUNOLIPOSOME; OLIGOMER; PLASMALOGEN; POLYARGININE; PROTEIN VP22; REACTIVE OXYGEN METABOLITE; RECOMBINANT DNA; STEROL CARRIER PROTEIN; TRANSACTIVATOR PROTEIN;

ADRENOLEUKODYSTROPHY; BIOCHEMISTRY; BIOENGINEERING; BIOGENESIS; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; CATALASE DEFICIENCY; CELL ORGANELLE; CELL PROTECTION; CHEMICAL MODIFICATION; CHONDRODYSPLASIA PUNCTATA; DETOXIFICATION; DISORDERS OF PEROXISOMAL FUNCTIONS; DRUG DELIVERY SYSTEM; DRUG DESIGN; ENZYME DEFICIENCY; FATTY ACID OXIDATION; GENETIC TRANSDUCTION; HUMAN; INBORN ERROR OF METABOLISM; METABOLISM; MOLECULAR BIOLOGY; NONHUMAN; OXALOSIS 1; OXIDATION; OXIDATIVE STRESS; PEROXISOME; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN TARGETING; PROTEIN TRANSPORT; REFSUM DISEASE; REVIEW; ZELLWEGER SYNDROME;

ACATALASIA; BIOLOGICAL TRANSPORT, ACTIVE; CATALASE; DRUG DELIVERY SYSTEMS; ENDOSOMES; HUMANS; HYDROGEN PEROXIDE; HYPEROXALURIA; INTRACELLULAR SPACE; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEPTIDES; PEROXISOMAL DISORDERS; PEROXISOMES; PROTEIN TRANSPORT; RECEPTORS, CYTOPLASMIC AND NUCLEAR; ZELLWEGER SYNDROME;

EID: 34548285477     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.06.005     Document Type: Review

References (59)

1. Wanders R.J., and Waterham H.R. Biochemistry of mammalian peroxisomes revisited. Annu. Rev. Biochem. 75 (2006) 295-332
2. Jansen G.A., and Wanders R.J. Alpha-oxidation. Biochim. Biophys. Acta. 1763 (2006) 1403-1412
3. Heiland I., and Erdmann R. Biogenesis of peroxisomes. Topogenesis of the peroxisomal membrane and matrix proteins. FEBS J. 272 (2005) 2362-2372
4. McCollum D., Monosov E., and Subramani S. The pas8 mutant of Pichia pastoris exhibits the peroxisomal protein import deficiencies of Zellweger syndrome cells- the PAS8 protein binds to the COOH-terminal tripeptide peroxisomal targeting signal, and is a member of the TPR protein family. J. Cell Biol. 121 (1993) 761-774
5. Terlecky S.R., Nutley W.M., McCollum D., Sock E., and Subramani S. The Pichia pastoris peroxisomal protein PAS8p is the receptor for the C-terminal tripeptide peroxisomal targeting signal. EMBO J. 14 (1995) 3627-3634
6. Marzioch M., Erdmann R., Veenhuis M., and Kunau W.-H. PAS7 encodes a novel yeast member of the WD-40 protein family essential for import of 3-oxoacyl-CoA thiolase, a PTS2-containing protein, into peroxisomes. EMBO J. (1994) 4908-4917
7. Keller G.A., Gould S.J., Deluca M., and Subramani S. Firefly luciferase is targeted to peroxisomes in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3264-3268
8. Gould S.J., Keller G.A., and Subramani S. Identification of a peroxisomal targeting signal at the carboxy terminus of firefly luciferase. J. Cell Biol. 105 (1987) 2923-2931
9. Gould S.J., Keller G.A., Hosken N., Wilkinson J., and Subramani S. A conserved tripeptide sorts proteins to peroxisomes. J. Cell Biol. 108 (1989) 1657-1664
10. Lametschwandtner G., Brocard C., Fransen M., Van Veldhoven P., Berger J., and Hartig A. The difference in recognition of terminal tripeptides as peroxisomal targeting signal 1 between yeast and human is due to different affinities of their receptor Pex5p to the cognate signal and to residues adjacent to it. J. Biol. Chem. 273 (1998) 33635-33643
11. Brocard C., and Hartig A. Peroxisome targeting signal 1: is it really a simple tripeptide. Biochim. Biophys. Acta. 1763 (2006) 1565-1573
12. Leon S., Goodman J.M., and Subramani S. Uniqueness of the mechanism of protein import into the peroxisome matrix: transport of folded, co-factor-bound and oligomeric proteins by shuttling receptors. Biochim. Biophys. Acta. 1763 (2006) 1552-1564
13. Fransen M., Terlecky S.R., and Subramani S. Identification of a human PTS1 receptor docking protein directly required for peroxisomal protein import. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 8087-8092
14. Rayapuram N., and Subramani S. The importomer - a peroxisomal membrane complex involved in protein translocation into the peroxisome matrix. Biochim. Biophys. Acta. 1763 (2006) 1613-1619
15. Fujiki Y., Matsuzono Y., Matsuzaki T., and Fransen M. Import of peroxisomal membrane proteins: the interplay of Pex13p- and Pex19p-mediated interactions. Biochim. Biophys. Acta. 1763 (2006) 1639-1646
16. Matsuzono Y., and Fujiki Y. In vitro transport of membrane proteins to peroxisomes by shuttling receptor Pex19p. J. Biol. Chem. 281 (2006) 36-41
17. Steinberg S.J., Dodt G., Raymond G.V., Braverman N.E., Moser A.B., and Moser H.W. Peroxisome biogenesis disorders. Biochim. Biophys. Acta. 1763 (2006) 1733-1748
18. White A.L., Modaff P., Holland-Morris F., and Pauli R.M. Natural history of rhizomelic chondrodysplasia punctata. Am. J. Med. Genet. 118 (2003) 332-342
19. Brosche T., and Platt D. The biological significance of plasmalogens in defense against oxidative damage. Exp. Gerontol. 33 (1998) 363-369
20. Farooqui A.A., and Horrocks L.A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7 (2001) 232-245
21. Wanders R.J., and Waterham H.R. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim. Biophys. Acta. 1763 (2006) 1707-1720
22. Wanders R.J., van Roermund C.W., Visser W.F., Ferdinandusse S., Jansen G.A., van den Brink D.M., Gloerich J., and Waterham H.R. Peroxisomal fatty acid alpha- and beta-oxidation in health and disease: new insights. Adv. Exp. Med. Biol. 544 (2003) 293-302
23. Danpure C.J., and Jennings P.R. Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 201 (1986) 20-24
24. Purdue P.E., Takada Y., and Danpure C.J. Identification of mutations associated with peroxisome-to-mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type 1. J. Cell Biol. 111 (1990) 2341-2351
25. Wood C.S., Koepke J.I., Teng H., Boucher K.K., Katz S., Chang P., Terlecky L.J., Papanayotou I., Walton P.A., and Terlecky S.R. Hypocatalasemic fibroblasts accumulate hydrogen peroxide and display age-associated pathologies. Traffic 7 (2006) 97-107
26. Terlecky S.R., Koepke J.I., and Walton P.A. Peroxisomes and aging. Biochim. Biophys. Acta. 1763 (2006) 1749-1754
27. Legakis J.E., Koepke J.I., Jedeszko C., Barlaskar F., Terlecky L.J., Edwards H.J., Walton P.A., and Terlecky S.R. Peroxisome senescence in human fibroblasts. Mol. Biol. Cell 13 (2002) 4243-4255
28. Purdue P.E., and Lazarow P.B. Targeting of human catalase to peroxisomes is dependent upon a novel COOH-targeting sequence. J. Cell Biol. 134 (1996) 849-862
29. Horiguchi H., Yurimoto H., Goh T.-K., Nakagawa T., Kato N., and Sakai Y. Peroxisome catalase in the methylotrophic yeast Candida boidinii: transport efficiency and metabolic significance. J. Bacteriol. 183 (2001) 6372-6383
30. Maynard E.L., Gatto Jr. G.J., and Berg J.M. Pex5p binding affinities for canonical and noncanonical PTS1 peptides. Proteins 55 (2004) 856-861
31. Kawada Y., Khan M., Sharma A.K., Ratnayake D.B., Dobashi K., Asayama K., Moser H.W., Contreras M.A., and Singh I. Inhibition of peroxisomal functions due to oxidative imbalance induced by mistargeting of catalase to cytoplasm is restored by vitamin E treatment in skin fibroblasts from Zellweger syndrome-like patients. Mol. Genet. Metab. 83 (2004) 297-305
32. Goth L., and Eaton J.W. Hereditary catalase deficiencies and increased risk of diabetes. Lancet 356 (2000) 1820-1821
33. Goth L., and Vitai M. Hypocatalasemia in hospital patients. Clin. Chem. 42 (2000) 341-342
34. Goth L. Lipid and carbohydrate chemistry in acatalasemia. Clin. Chem. 42 (2000) 564-566
35. Yildirim O., Ates N.A., Tamer L., Musler N., Ercan B., Atik U., and Kanik A. Changes in antioxidant enzyme activity and malondialdehyde levels in patients with age-related macular degeneration. Opthalmologica 218 (2004) 202-206
36. Sheikh F.G., Pahan K., Khan M., Barbosa E., and Singh I. Abnormality in catalase import into peroxisomes leads to a severe neurological disorder. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2961-2966
37. Keenan R.J., Freymann D.M., Stroud R.M., and Walter P. The signal recognition particle. Annu. Rev. Biochem. 70 (2001) 755-775
38. Neupert W., and Herrmann J.M. Translocation of proteins into mitochondria. Annu. Rev. Biochem. 76 (2007) 6.1-6.21
39. Murriel C.L., and Dowdy S.F. Influence of protein transduction domains on intracellular delivery of macromolecules. Exp. Opin. Drug Del. 3 (2006) 739-746
40. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
41. Nagahara, Vocero-Akbani A.M., Snyder E.L., Ho A., Latham D.G., Lissy N., Becker-Hapak M., Ezhevsky S.A., and Dowdy S.F. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat. Med. 4 (1998) 1449-1452
42. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. The third helix of the antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994) 10444-10450
43. Perez F., Joliot A., Bloch-Gallego E., Zahraoui A., Triller A., and Prochiantz A. Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide. J. Cell Sci. 102 (1992) 717-722
44. Elliot G., and O'Hare P. Intercellular trafficking and protein delivery by a herpes virus structural protein. Cell 88 (1997) 223-233
45. Mitchell D.J., Kim D.T., Steinman L., Fathman C.G., and Rothbard J.B. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56 (2000) 318-325
46. Tyagi M., Rusnati M., Presta M., and Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 276 (2001) 3254-3261
47. Potocky T.B., Menon A.K., and Gellman S.H. Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. J. Biol. Chem. 278 (2003) 50188-50194
48. Fischer R., Kohler K., Fotin-Mleczek M., and Brock R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. J. Biol. Chem. 279 (2004) 12625-12635
49. Wadia J.S., Stan R.V., and Dowdy S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004) 310-315
50. Michiue H., Tomizawa K., Wei F.Y., Matsushita M., Lu Y.F., Ichikawa T., Tamiya T., Date I., and Matsui H. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhance the antitumor potency of polyarginine-mediated p53 protein transduction. J. Biol. Chem. 280 (2005) 8285-8289
51. Adams S.R., and Tsien R.Y. Imaging the influx of cell-penetrating peptides. In: Langel U. (Ed). Handbook of Cell-Penetrating Peptides (2007), CRC Press 505-513
52. Morris M.C., Depollier J., Mery J., Heitz F., and Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat. Biotechnol. 19 (2001) 1173-1176
53. Morris M.C., Vidal P., Chaloin L., Heitz F., and Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res. 25 (1997) 2730-2736
54. Deshayes S., Heitz A., Morris M.C., Charnet P., Divita G., and Heitz F. Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry 43 (2004) 1449-1457
55. Schnyder A., and Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2 (2005) 99-107
56. Yabe Y., Kobayashi N., Nishikawa M., Mihara K., Yamashita F., Takakura Y., and Hashida M. Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharm. Res. 19 (2002) 1815-1821
57. Yabe Y., Nishikawa M., Tamada A., Takakura Y., and Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J. Pharmacol. Exp. Ther. 289 (1999) 1176-1184
58. Kozower B.D., Christofidou-Solomidou M., Sweitzer T.D., Muro S., Buerk D.G., Solomides C.C., Albelda S.M., Patterson G.A., and Muzykantov V.R. Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury. Nat. Biotechnol. 21 (2003) 392-398
59. Chauhan A., Tikoo A., Kapur A.K., and Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control. Release 117 (2007) 148-162